Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT02689206

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02689206
  • EudraCT 2015-004790-32
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Germany, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02689206. Randomized; double masking; primary purpose treatment. Start 2016-02-17 (actual); primary completion 2017-01-25 (actual). Results posted on 2018-05-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Condition
Anaemia
Intervention (Drug)
GSK1278863
Intervention (Drug)
GSK1278863 matching Placebo
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct02689206
Content hash
c217d585cd15f920126ea8a9cdb5bba3c549a257a0dbafb4e4cb79ea40960fd7